ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2014
Interstitial brachytherapy for eyelid carcinoma. Outcome analysis in 60 patients.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Organ-sparing treatment of penile cancer with interstitial pulsed-dose-rate brachytherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2016Trial
- Regional nodal relapse in surgically staged Merkel cell carcinoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2015Trial
- Modern brachytherapy modalities vs. external beam radiotherapy in post-operative non-melanoma skin cancer: A systematic review.Journal of contemporary brachytherapy · 2026Review
- High-dose-rate brachytherapy for eyelid carcinoma: Implant technique and review.Journal of contemporary brachytherapy · 2025Article
- Protective eye device for eyelid brachytherapy: Technical report of an innovative personalized method.Annals of medicine and surgery (2012) · 2025Article
- The irreplaceable art of brachytherapy: A technical note on interstitial high-dose-rate interventional radiotherapy (brachytherapy) in eyelid tumors.Journal of contemporary brachytherapy · 2025Article
- Brachytherapy for eyelid cancers: Re-defining outcomes and esthetics in rare histologies.Journal of contemporary brachytherapy · 2025Article
- Interstitial brachytherapy for periocular nonmelanoma skin cancers: Impact on organ and function preservation.Technical innovations & patient support in radiation oncology · 2024Article
- Post-operative interventional radiotherapy (brachytherapy) in advanced ocular surface and eyelid tumors as an alternative to surgical retreatment.European journal of ophthalmology · 2024Article
- Treatment of Basal Cell Carcinoma of the Lower Eyelid With High-Dose-Rate Brachytherapy.Cureus · 2024Article
- Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye.Cancers · 2021Article
- High-dose-rate interstitial brachytherapy for a bulky sebaceous carcinoma of the eyelid: A case report.Clinical case reports · 2019Article
- Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.The Journal of clinical and aesthetic dermatology · 2017Article
- Brachytherapy in non melanoma skin cancer of eyelid: a systematic review.Journal of contemporary brachytherapy · 2015Review
- Postoperative interstitial brachytherapy in eyelid cancer: long term results and assessment of Cosmesis After Interstitial Brachytherapy scale.Journal of contemporary brachytherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEyelid cancer is a therapeutic challenge due to the cosmetic and functional implications of this anatomical region and the objectives of therapy are tumor control, functional and cosmetic outcome.
aimThe present study was performed to analyze local control, toxicity, functional and cosmetic results in patients with eyelid carcinoma treated by interstitial brachytherapy. MATERIAL AND
methodsIn this study 60 patients with eyelid carcinoma were treated by interstitial brachytherapy using iridium ((192)Ir) wires with a linear activity of 1.2-1.7 mCi/cm. The prescription dose was 51-70 Gy (mean 65 Gy, median 66 Gy).
resultsOf the 60 patients 51 (85.0 %) had received no prior treatment, 4 (6.7 %) had received previous surgery with positive or close margins and 5 (8.3 %) had suffered local recurrence after surgery. Of the tumors 52 (86.7 %) were basal cell carcinoma, 7 (11.7 %) squamous cell carcinoma and 1 (1.7 %) Merkel cell carcinoma. Clinical stage of the 51 previously untreated tumors was 38 T1N0, 12 T2N0 and 1 T3N0. Mean follow-up was 92 months (range 6-253 months). Local control was maintained in 96.7 % of patients. Late effects higher than grade 2 were observed in 3.0 % of cases. Functional and cosmetic outcomes were optimal in 68.4 % of patients.
conclusionInterstitial brachytherapy for carcinoma of the eyelid can achieve local control, cosmetic and functional results comparable to those of surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.